** Shares of biopharma firm Ocular Therapeutix OCUL.O fall 13% to $6.21
** Company posts quarterly revenue of $17.08 million compared with analysts' estimates of $17.20 million, according data compiled by LSEG
** Reports Q4 loss of 29 cents per share compared to analysts' estimates of 25 cents
** Company delays data from late-stage study testing its drug, axpaxli, to treat wet age-related macular degeneration (wet AMD) to Q1 2026 from Q4 2025 as the FDA allows changes to study design through Special Protocol Agreement $(SPA.UK)$
** Wet AMD is a condition where abnormal blood vessels grow under the retina, leading to vision loss
** OCUL has fallen 28.2% in the last 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。